DouglasGMcNeelMD

Oncology • Madison, WI

Associate Professor, Medicine, University of Wisconsin Medical School

Join to view full profile

Dr. McNeel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McNeel's full profile

Already have an account?

Office
600 Highland Ave
Madison, WI 53792
Phone+1 608-265-1700

Fax+1 608-266-6020

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1996 - 2000
University of WashingtonResidency, Internal Medicine, 1994 - 1996
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1994

Certifications & Licensure

WI State Medical License 2001 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma Start of enrollment: 2002 Oct 01
Completed
Phase 1
Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer Start of enrollment: 2005 Mar 01
Completed
Phase 1
Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy Start of enrollment: 2003 Apr 01
Completed
Phase 2
CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer Start of enrollment: 2008 Jul 01
Terminated
Phase 1
Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer Start of enrollment: 2009 Mar 16
Completed
Phase 2
Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer Start of enrollment: 2009 Jun 01
Withdrawn
Phase 1
Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Start of enrollment: 2010 Aug 01
Terminated
Phase 2
Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer Start of enrollment: 2011 May 23
Completed
Phase 2
Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer Start of enrollment: 2013 May 20
Completed
Phase 2
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer Start of enrollment: 2013 Feb 15
Completed
Phase 1
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer Start of enrollment: 2019 Oct 21
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

5 citations
Toll-like receptor agonists as cancer vaccine adjuvants.
Donghwan Jeon, Ethan Hill, Douglas G McNeel
Human Vaccines & Immunotherapeutics. 2024-12-31
Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer.
Tommaso P Tonelli, Jens C Eickhoff, Laura E Johnson, Glenn Liu, Douglas G McNeel
Human Vaccines & Immunotherapeutics. 2024-12-31
Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy.
Anusha Muralidhar, Melissa Gamat-Huber, Sita Vakkalanka, Douglas G McNeel
Journal for Immunotherapy of Cancer. 2024-05-20

Journal Articles

Therapeutic Cancer Vaccines: How Much Closer Are We?
Douglas McNeel, MD, Biodrugs

Press Mentions

Future of Health: Cancer VaccinesMay 11th, 2022
The Society for Immunotherapy of Cancer (SITC) Invites You to Attend the Virtual Press Briefing of the Society’s 36th Anniversary Annual MeetingNovember 2nd, 2021
2021 Urology Care Foundation Research Scholar Awardees AnnouncedApril 13th, 2021
Join now to see all

Grant Support

Androgen Receptor Targeted Vaccines For Prostate CancerNational Cancer Institute2010–2012
Physician Scientist Training In Cancer MedicineNational Cancer Institute2008–2011
Pilot Trial Of A DNA Vaccine Encoding PAP In Patients With Prostate CancerNational Cancer Institute2008–2009
Phase I Study Of A Dna-Based Vaccine Targeting Prostatic Acid Phosphatase (PAP)National Center For Research Resources2007
Phase I Study Of A Dna-Based Vaccine Targeting Prostatic Acid PhosphataseNational Center For Research Resources2006
A Phase 1 Study/Dna-Based Vaccine VS Prostatic Acid PASENational Center For Research Resources2002–2006
Pilot -- Identification Of Antigens Of ProstateNational Institute Of Diabetes And Digestive And Kidney Diseases2003